This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...

Blueprint Medicines Corp (NASDAQ:BPMC) reported a challenging fourth quarter for 2024, missing analyst expectations for both earnings per share (EPS) and revenue. The company posted an EPS of -0.79, ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...